Sonnet BioTherapeutics
SONN
SONN was delisted on the 2nd of December, 2025.
16 hedge funds and large institutions have $1.65M invested in Sonnet BioTherapeutics in 2021 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
23% more funds holding
Funds holding: 13 → 16 (+3)
0% more ownership
Funds ownership: 0% → 0% (+0%)
3% less capital invested
Capital invested by funds: $1.69M → $1.65M (-$43K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$366K |
| 2 |
VF
Virtu Financial
New York
|
+$149K |
| 3 |
Renaissance Technologies
New York
|
+$128K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$25.8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$21.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$2.87K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Vanguard Group
Malvern,
Pennsylvania
| $734K | – | – | – |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $465K | +$366K | +255 | +126% |
|
|
3
Renaissance Technologies
New York
| $138K | +$128K | +89 | +189% |
|
|
VF
4
Virtu Financial
New York
| $106K | +$149K | +104 | New |
|
5
BlackRock
New York
| $76K | – | – | – |
|
6
State Street
Boston,
Massachusetts
| $26K | – | – | – |
|
|
ASN
7
Advisory Services Network
Atlanta,
Georgia
| $21K | +$11.5K | +8 | +62% |
|
8
T. Rowe Price Associates
Baltimore,
Maryland
| $19K | – | – | – |
|
|
9
UBS Group
Zurich,
Switzerland
| $19K | +$21.5K | +15 | +375% |
|
|
10
Northern Trust
Chicago,
Illinois
| $18K | +$25.8K | +18 | New |
|
|
TSS
11
Two Sigma Securities
New York
| $13K | -$2.87K | -2 | -13% |
|
|
BPA
12
Beacon Pointe Advisors
Newport Beach,
California
| $7K | – | – | – |
|
|
MSFS
13
Main Street Financial Solutions
Newtown,
Pennsylvania
| $4K | – | – | – |
|
|
IA
14
IFP Advisors
Tampa,
Florida
| $1K | – | – | – |
|
15
Morgan Stanley
New York
| $1K | – | – | – |
|
|
TRCT
16
Tower Research Capital (TRC)
New York
| $1K | +$1.44K | +1 | New |
|
SONN Hedge Fund Activity: Q4 2021 in Review
16 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Sonnet BioTherapeutics (SONN) for Q4 2021, worth a combined $1.65M — down 2.5% from $1.69M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new SONN positions and 0 closed out — a net gain of 3 holders — while 4 added to existing stakes and 1 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $366K. The largest seller was Two Sigma Securities, cutting an estimated $2.87K.
- 16 institutional investors held Sonnet BioTherapeutics (SONN) as of Q4 2021, up from 13 in Q3 2021.
- Funds reported $1.65M of Sonnet BioTherapeutics stock for Q4 2021, down 2.5% quarter-over-quarter.
- 3 funds opened new Sonnet BioTherapeutics positions in Q4 2021 and 0 closed out, a net change of +3 holders.
- The largest Sonnet BioTherapeutics buyer in Q4 2021 was Geode Capital Management, an estimated $366K added.
- The largest Sonnet BioTherapeutics seller in Q4 2021 was Two Sigma Securities, an estimated $2.87K sold.
Based on aggregated 13F filings for Q4 2021.